uBriGene Biosciences completes several hundred million yuan Series C round funding
uBriGene Biosciences completes several hundred million yuan Series C round funding, focusing on global cell & gene therapy and...
top of page
- Dec 23, 2022
- 4 min
Correcting visual impairment: VGR-R01 project IND application accepted by Center for Drug Evaluation
A VGR-R01 project IND application from uBriGene partner Vitalgen has been accepted by the CDE, aiming to correct visual impairment On...
- Apr 21, 2022
- 2 min
Assisted Clinical Application of Gene Therapy for Hemophilia B of Vitalgen Accepted by NMPA
On April 21, 2022, according to the Chinese CDE (Center for Drug Evaluation) official website, the clinical trial application of VGB-R04...
- Jan 27, 2022
- 3 min
Assisted Clinical Application of Gene Therapy in Ophthalmology of Innostellar Accepted by NMPA
On January 26, 2022, pertaining to the announcement of Chinese CDE (Center for Drug Evaluation) official website, the clinical trial...
bottom of page